<div id="readability-page-1"><p>Patriot Financial Group Insurance Agency LLC lifted its stake in  AbbVie Inc. (NYSE:ABBV - Free Report) by 184.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,249 shares of the company's stock after purchasing an additional 9,242 shares during the period. Patriot Financial Group Insurance Agency LLC's holdings in AbbVie were worth $3,299,000 at the end of the most recent quarter.</p><ul><li>3 Dividend Growth Stocks Analysts Are Upgrading for 2026</li></ul><p>Other institutional investors also recently added to or reduced their stakes in the company. Hobart Private Capital LLC increased its position in shares of  AbbVie by 4.4% during the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company's stock worth $261,000 after acquiring an additional 48 shares during the period.  Rise Advisors LLC boosted its holdings in shares of  AbbVie by 3.4% in the third quarter. Rise Advisors LLC now owns 1,451 shares of the company's stock valued at $336,000 after purchasing an additional 48 shares during the period.  Sivia Capital Partners LLC grew its stake in  AbbVie by 1.1% in the second quarter. Sivia Capital Partners LLC now owns 4,571 shares of the company's stock worth $848,000 after purchasing an additional 51 shares in the last quarter.  FF Advisors LLC increased its holdings in  AbbVie by 3.6% during the 2nd quarter. FF Advisors LLC now owns 1,539 shares of the company's stock worth $286,000 after purchasing an additional 53 shares during the period.  Finally, Landaas &amp; Co. WI ADV increased its holdings in  AbbVie by 1.1% during the 2nd quarter. Landaas &amp; Co. WI ADV now owns 4,955 shares of the company's stock worth $920,000 after purchasing an additional 53 shares during the period. Hedge funds and other institutional investors own  70.23% of the company's stock. </p><h2>AbbVie Stock Performance</h2><p>Shares of AbbVie stock opened at $222.87 on Friday. The company has a market capitalization of $393.89 billion, a PE ratio of 168.84, a P/E/G ratio of 1.27 and a beta of 0.36. The company has a 50-day simple moving average of $226.70 and a two-hundred day simple moving average of $210.69. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. </p><ul><li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li></ul><p>AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to analysts' expectations of $15.58 billion. During the same period last year, the business earned $3.00 EPS. The company's revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.  Research analysts expect that  AbbVie Inc. will post 12.31 EPS for the current fiscal year. </p><h2>AbbVie Increases Dividend</h2><p>The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This is an increase from AbbVie's previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie's dividend payout ratio  is presently 496.97%. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p>ABBV has been the topic of a number of recent research reports. DZ Bank downgraded AbbVie from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $237.00 price target on the stock. in a research report on Tuesday, November 4th. Citigroup lowered their price objective on shares of AbbVie from $240.00 to $235.00 and set a &#34;neutral&#34; rating for the company in a research note on Monday, November 3rd. BMO Capital Markets increased their target price on shares of AbbVie from $215.00 to $240.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, September 12th. Erste Group Bank lowered shares of AbbVie from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, October 14th. Finally, JPMorgan Chase &amp; Co. upped their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued  a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $245.84.</p><p><b>Check Out Our Latest Analysis on AbbVie</b></p><h2>About AbbVie</h2> (Free Report)<p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than AbbVie</li><li>Golden Cross Stocks: Pattern, Examples and Charts </li><li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li><li>The How And Why of Investing in Oil Stocks</li><li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li><li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li><li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li></ul><p><strong>Want to see what other hedge funds are holding ABBV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>Patriot Financial Group Insurance Agency LLC increased its stake in AbbVie Inc. by 184.6% in the third quarter, owning 14,249 shares worth $3,299,000. Other institutional investors also adjusted their holdings. AbbVie reported Q3 earnings of $1.86 per share, beating estimates, with revenue up 9.1% year-over-year. The company raised its quarterly dividend to $1.73 per share. Analysts have mixed ratings on AbbVie, with some downgrading and others raising price targets.</p>

Patriot Financial Group Insurance Agency LLC Raises Stake in AbbVie Inc. $ABBV